| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Lipoprotein-associated phospholipase A2 (Lp-PLA2). Darapladib-impurity is a byproduct of Darapladib synthesis and has a similar mechanism of action but lower potency. Darapladib inhibits Lp-PLA2. The impurity is used in research to study the properties of Darapladib.
|
|---|---|
| ln Vitro |
In vitro activity data for Darapladib-impurity is not well-documented. The compound is an impurity of Darapladib and has a similar chemical structure but lower potency. Darapladib inhibits Lp-PLA2. The impurity is used in research applications.
|
| ln Vivo |
In vivo activity data for Darapladib-impurity is not well-documented. The compound is an impurity of Darapladib and is used in research to study the properties of Darapladib. Darapladib inhibits Lp-PLA2.
|
| Enzyme Assay |
In vitro enzymatic or receptor binding assays for Darapladib-impurity may involve the use of Lp-PLA2 enzyme assays. The compound's ability to inhibit Lp-PLA2 can be assessed, although it is expected to have lower potency than Darapladib. However, specific assay protocols are not well-documented.
|
| Cell Assay |
In vitro cell-based assays for Darapladib-impurity are not well-documented. The compound is an impurity of Darapladib and is used in research applications. Specific cell-based assay protocols have not been extensively characterized.
|
| Animal Protocol |
In vivo animal studies for Darapladib-impurity are not well-documented. The compound is an impurity of Darapladib and is used in research to study the properties of Darapladib.
|
| ADME/Pharmacokinetics |
Darapladib-impurity has a molecular weight of 666.77 and a molecular formula of C36H38F4N4O2S. It has a CAS number of 1389264-17-8. The compound typically exists as a solid at room temperature. It has a purity of 98.04% (HPLC). It is an impurity of Darapladib.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Darapladib-impurity. The compound is for research use only and is not intended for human therapeutic use. It is an impurity and is used to study the properties of Darapladib.
|
| Additional Infomation |
Darapladib-impurity is a byproduct of the synthesis of Darapladib. It has a molecular weight of 666.77 and a molecular formula of C36H38F4N4O2S. The compound has a CAS number of 1389264-17-8. It has a similar chemical structure and mechanism of action to Darapladib but with lower potency. Darapladib inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2). The compound is for research use only and has not been approved for clinical use.
|
| Molecular Formula |
C36H38F4N4O2S
|
|---|---|
| Molecular Weight |
666.77
|
| Exact Mass |
666.265
|
| CAS # |
1389264-17-8
|
| PubChem CID |
74889411
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
766.5±60.0 °C at 760 mmHg
|
| Flash Point |
417.4±32.9 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
9.23
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
47
|
| Complexity |
934
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CC)CCN(C(COC1=C2C(CCC2)=NC(SCC2=CC=C(F)C=C2)=N1)=O)CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1
|
| InChi Key |
KELIVYXNVITYCV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H38F4N4O2S/c1-3-43(4-2)20-21-44(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-46-34-31-6-5-7-32(31)41-35(42-34)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
|
| Chemical Name |
N-[2-(diethylamino)ethyl]-2-[[2-[(4-fluorophenyl)methylsulfanyl]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]oxy]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
|
| Synonyms |
Darapladib impurity; Darapladib-impurity
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4998 mL | 7.4988 mL | 14.9977 mL | |
| 5 mM | 0.3000 mL | 1.4998 mL | 2.9995 mL | |
| 10 mM | 0.1500 mL | 0.7499 mL | 1.4998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
